When Should We Start Sodium-Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention.

Abstract

www.ECRjournal.com Sodium–glucose co-transporter (SGLT2) inhibitors were primarily developed as anti-diabetic drugs to increase the excretion of glucose in the urine. However, SGLT2 inhibitors have been reported to have multifactorial effects, such as renal protection and improvement of myocardial energy metabolism and anaemia symptoms, which may exert protection against progression of heart failure beyond their mere diuretic action.